

## SNPs of Importance for Venous Thromboembolism Risk

Gene	Protein change	Nucleotide change	Marker	Genotype	Results
F5	Arg534Gln	1601G>A	rs6025	G/G	Normal risk
F2		*97G>A	rs1799963	G/G	Normal risk
MTHFR	Ala222Val	665C>T	rs1801133	G/A	
MTHFR	Glu429Ala	1286A>C	rs1801131	G/T	

## PGx Report - Internal Medicine

Type: Drugs Prescribed for the Modulation of Respiratory Function

Drug Class	Generic	Primary Mechanism Involved	Other Mechanisms Involved	Used As Directed	May Have Decreased Efficacy	May Have Increased Toxicity
Respiratory						
Anticholinergic	<a href="#">Umeclidinium</a>	CYP2D6		●		
	<a href="#">Aclidinium</a>	CYP2D6	CYP3A4, CYP3A5	●		
Beta2-adrenergic agonist	<a href="#">Arformoterol</a>	CYP2D6	CYP2C19	●		
	<a href="#">Indacaterol</a>	CYP3A4	CYP3A5, CYP1A2, CYP2D6	●		
	<a href="#">Formoterol</a>	CYP2D6	CYP2C19, CYP2C9	●		
	<a href="#">Salmeterol</a>	CYP3A4	CYP3A5	●		
	<a href="#">Vilanterol</a>	CYP3A4	CYP3A5	●		
Corticosteroid	<a href="#">Budesonide</a>	CYP3A4	CYP3A5	●		
	<a href="#">Fluticasone</a>	CYP3A4	CYP3A5	●		
	<a href="#">Mometasone</a>	CYP3A4	CYP3A5	●		
Phosphodiesterase inhibitor	<a href="#">Roflumilast</a>	CYP3A4	CYP1A2, CYP3A5	●		
	<a href="#">Theophylline</a>	CYP1A2		●		
5-lipoxygenase inhibitor	<a href="#">Zileuton</a>	CYP1A2	CYP2C9, CYP3A4, CYP3A5	●		
Leukotriene receptor-1 antagonist	<a href="#">Montelukast</a>	CYP3A4	CYP2C9, CYP3A5, SLCO2B1, ABCC1	●		
	<a href="#">Pranlukast</a>	CYP3A4	CYP3A5	●		
	<a href="#">Zafirlukast</a>	CYP2C9	CYP3A4, CYP3A5	●		
Treatment of cystic fibrosis (specific mutations in the CFTR gene)	<a href="#">Ivacaftor</a>	CYP3A4	CYP3A5, CFTR	●		

Abbreviations: CFTR, Cystic fibrosis transmembrane conductance regulator.